Stock Events

Evaxion Biotech A/S 

$2.91
18
+$0.02+0.69% Today

Statistics

Day High
3.14
Day Low
2.89
52W High
13.82
52W Low
2.26
Volume
44,932
Avg. Volume
25,266
Mkt Cap
15.64M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

29MayExpected
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-1.6
-1.07
-0.53
0
Expected EPS
-0.55
Actual EPS
-1.6

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVAX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap46.55B
Moderna is a leader in mRNA technology, directly competing with Evaxion's focus on developing vaccines and treatments using similar technology.
BioNTech
BNTX
Mkt Cap20.19B
BioNTech competes in the mRNA vaccine space, similar to Evaxion's approach to vaccine development, making them direct competitors.
Novavax
NVAX
Mkt Cap1.84B
Novavax is involved in the development of vaccines for infectious diseases, competing with Evaxion's infectious disease vaccine programs.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is focused on gene editing, a technology that can be seen as complementary or competitive to Evaxion's AI-driven approach to drug development.
Intellia Therapeutics
NTLA
Mkt Cap2.49B
Intellia Therapeutics is another company working on CRISPR technology, potentially competing with Evaxion's efforts in genetic-based therapies.
Editas Medicine
EDIT
Mkt Cap455.6M
Editas Medicine operates in the gene editing space, which could compete with Evaxion's technology in developing treatments for various diseases.
Pfizer
PFE
Mkt Cap163.88B
Pfizer is a large pharmaceutical company with a broad portfolio that includes vaccines and treatments that could compete with Evaxion's products.
Johnson & Johnson
JNJ
Mkt Cap360.71B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines and therapeutics that could compete with Evaxion's pipeline.
Gilead Sciences
GILD
Mkt Cap87.16B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, and influenza, competing with Evaxion's infectious disease focus.
Merck &
MRK
Mkt Cap323.59B
Merck is a global healthcare company that develops vaccines and therapeutics, including for infectious diseases, competing with Evaxion's product pipeline.

Analyst Ratings

11$Average Price Target
The highest estimate is $14.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Show more...
CEO
Employees
49
Country
US
ISIN
US29970R1059

Listings